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Introduction
Cancer is a major public health problem in many parts of the 
world.1 Thyroid cancer is one of the least deadly cancers. The 5-year 
survival rate for all thyroid cancer is about 97%. Thyroid cancer 
is different from many other adult cancers in that it is commonly 
diagnosed in young people. Nearly 2 of 3 cases are found in people 
between the age of 20 and 55.2
The age–and gender-adjusted incidence of thyroid cancer has 
increased faster than that of any other malignancy in recent years. 
The American cancer Society in recent estimate for thyroid cancer 
in the United States (2010) showed that about 44, 670 new cases 
of thyroid cancer will occur (33,930 in women and 10,740 in men). 
Thyroid cancer will cause about 1, 690 deaths (960 women and 
730 men).3
Over the past three decades, the incidence of thyroid cancer 
(TC)  has  significantly  increased  worldwide,  rising  from  a  rate 
of 3.6 /100,000 in 1973 to 8.7/100,000 in 2002, without any 
change in the mortality rate.4 The increase is almost exclusively 
due to a rise in papillary cancer rates, this being attributed to both 
environmental  radiation  and  increased  diagnostic  scrutiny.5  In 
areas which have not been afflicted by nuclear fallout, the annual 
incidence of TC ranges from 2.0 to 3.8/100,000 in women and 
from 1.2 to 2.6/100,000 in men.6
Significant  differences  in  TC  incidence  have  been  reported 
among various regions, with Hawaii, the Philippines and Iceland 
presenting the greatest incidence worldwide. This phenomenon 
possibly suggests that common environmental influences in these 
regions may be responsible for the strikingly high rates.7,8
The aim of this communication is to highlight the guideline for 
surgical treatment of well differentiated thyroid cancer.
Classification and Pathology
Thyroid  cancer  can  arise  from  epithelial  and  non-epithelial 
tissue. Thyroid follicular epithelial-derived cancers are: papillary, 
follicular and anaplastic. Other malignant diseases of the thyroid 
include medullary thyroid cancer, primary lymphoma, sarcomas 
and metastases to the thyroid gland.
Papillary and follicular cancers are considered differentiated 
cancer. Papillary carcinoma is more common but in population with 
low dietary iodine intake, follicular and anaplastic predominate.9
Surgical Treatment
As in the management of other cancers, once the diagnosis of 
differentiated  thyroid  cancer  is  established,  several  treatment 
options may be considered such as surgery, radioiodine therapy, 
external beam radiation and thyroid hormone suppression.
The treatment depends on the patient’s age, the extent of the 
disease and the co-morbid conditions. Evidence-based guidelines 
published by the American Thyroid Association (ATA) in 2009 
10  for  management  of  thyroid  cancer  provide  recommendation 
for choice of therapy. This is in addition to those of National 
Comprehensive  Cancer  Network  (NCCN),11  and  European 
consensus group (ECG).12 Surgery is the main stay of treatment for 
differentiated thyroid cancer. This can be total thyroidectomy, near 
total thyroidectomy and unilateral lobectomy and isthmusectomy. 
Though the primary therapy for differentiated thyroid cancer is 
surgery, there is controversy about how much of thyroid tissue 
should be removed. It is difficult to conclude on optimal operation 
since there are no prospective randomized clinical trials.
The  aim  of  surgery  in  differentiated  thyroid  carcinoma  is 
to eradicate all tumour foci, cure the most number of patients, 
reduce recurrence and mortality rate and provide good quality 
life. Increasing body evidence suggests that most patients with 
differentiated thyroid cancer are best served by total (or near total) 
thyroidectomy, followed by radioiodine therapy for any remaining 
thyroid tissue and/ or microscopic foci.
Total thyroidectomy is complete removal of the thyroid gland 
while near total thyroidectomy is similar to total thyroidectomy 
with  preservation  of  the  posterior  thyroid  capsule  of  the  lobe 
contralateral to the thyroid tumor. This is in contradistinction 
from  unilateral  lobectomy  and  isthmusectomy  in  which  the 
contralateral  lobe  is  left  in-situ.  It  has  been  generally  agreed 
that subtotal thyroidectomy in which several grams of thyroid 
tissue are preserved bilaterally, is adequate not just because of 
high recurrence rate but also because of high complication rate if 
subsequent surgery is required.13,14,15Oman Medical Specialty Board
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Total thyroidectomy is recommended for most patients with 
thyroid cancer for the following reasons: 
1. Foci of papillary cancer are found in both lobes in up to 36 to 
85 percent.16, 17, 18, 19
2.   Between 5 and 10 percent of recurrences of thyroid cancer are 
in the contralateral lobe.20
3.   One-half of the patients who die from recurrent thyroid cancer 
die from complications of central neck recurrence.19
4.   Radioiodine ablation of thyroid bed remnant and treatment of 
metastatic disease is facilitated by resection of as much thyroid 
tissue as possible. 
5.   The specificity of measurements of serum thyroglobulin as a 
tumor marker is facilitated by removal of nearly all normal 
thyroid tissue. 
6.  During  follow  up,  ultrasonography  (US)  often  identifies 
nonspecific abnormalities in the remaining contralateral lobe 
that is a source of concern to both the clinician and the patient. 
While  only  minorities  of  these  US-detected  abnormalities 
prove  to  be  thyroid  cancer,  they  usually  lead  to  additional 
testing and often additional surgery.
The  benefit  of  total  or  near  total  thyroidectomy  is  further 
supported by publication of results from the National Thyroid 
Cancer  Treatment  Cooperative  Study  Group  (NTCTCG)  in 
2006.21 Additional data from the 2009 NTCTCG showed a lower 
recurrence rate in patients with multifocal microscopic papillary 
cancer who had total or near total thyroidectomy.22 Proponent 
of  unilateral  lobectomy  and  isthmusectomy  argue  in  support 
of this procedure because of absence of a survival benefit with 
total thyroidectomy,  23 and fewer complications with unilateral 
surgery.24
With the current information it can be concluded that total 
thyroidectomy  is  recommended  if  primary  tumor  is  1.0cm  in 
diameter or greater, there is extra thyroidal extension of tumor or 
there are metastases. It is also the operation of choice in all patients 
with thyroid cancer as a result of exposure to ionizing radiation 
of the head and neck.25 Total thyroidectomy, however, requires 
the  services  of  an  experienced  thyroid  surgeon  to  minimize 
complications. If an experienced thyroid surgeon is not available, 
patient should be referred elsewhere or a near total thyroidectomy 
should be preferred. If the tumor is less than 1.0cm in diameter 
and  confined  to  one  lobe  of  the  gland,  unilateral  lobectomy 
and  isthmusectomy  is  acceptable  because  30  year  survival  rate 
approaches 100 percent.26
Since  papillary  thyroid  carcinoma  commonly  metastases  to 
the cervical lymph nodes, neck dissection is part of the surgical 
treatment.  The  role  of  prophylactic  neck  dissection  for  well 
differentiated thyroid cancer remains controversial. It is however 
generally  agreed  that  therapeutic  neck  dissection  should  be 
performed  in  patients  with  papillary  thyroid  cancer  who  have 
visibly  involved  nodes.10,14  The  lymph  nodes  can  be  palpated 
clinically; nonpalpable metastatic nodes in up to 20 percent of 
patients can be preoperatively diagnosed using ultrasound. This 
can be useful in taking a decision on the need for therapeutic neck 
dissection.
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